ABT vs AEE Stock Comparison

Scores Breakdown

Metric	ABT	AEE
📈 Growth	18/30	8/30
💰 Profitability	17/20	16/20
🏦 Financial Health	18/20	12/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	4/10	6/10
Overall Score	71/100	52/100

Side-by-Side Summaries

ABT Analysis	AEE Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Over 8 quarters, Revenue moved from about $2.17B (2024Q4) to a high of about $2.70B (2025Q3) and ended around $2.09B in 2026Q2. Net income (to parent) rose from about $207M (2024Q4) to roughly $314M (2026Q2), indicating improving profitability despite revenue swings. The trend shows volatility but a constructive late-cycle improvement with strong operating performance in several quarters. 💰 Margins & Cash Flow Operating margins have hovered in the low-to-mid 20s percent on average, with standout quarters in 2025Q1–Q2 (~32–34%) and weaker margins in 2024Q3–Q4 (~9–10%). Net cash from operating activities remained positive in all periods, including a peak near $0.96B (2025Q4); investing cash flow was consistently negative, reflecting capital intensity. Financing activity varied, contributing to liquidity in several quarters. 🛡️ Balance Sheet & Liquidity Total Liabilities run in the mid-to-high $30s billions with equity around $12–14B, implying leverage near 2.5–3x. Long-term Debt remained substantial (roughly $18–20B across periods). Current assets (~~$2.0–$2.7B) vs. current liabilities (~~$3.0–$5.0B) indicate tight near-term liquidity, but the regulated earnings base provides resilience and steady cash generation. ⚠️ Key Drivers & Risks Drivers: Regulated utility framework and capital investment cycle; stable, commodity-insensitive cash flow. Risks: High leverage/interest-rate sensitivity; regulatory/regulatory cost pressures and weather-related demand variability.

ABT Analysis

AEE Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Over 8 quarters, Revenue moved from about $2.17B (2024Q4) to a high of about $2.70B (2025Q3) and ended around $2.09B in 2026Q2. Net income (to parent) rose from about $207M (2024Q4) to roughly $314M (2026Q2), indicating improving profitability despite revenue swings. The trend shows volatility but a constructive late-cycle improvement with strong operating performance in several quarters.

💰 Margins & Cash Flow

Operating margins have hovered in the low-to-mid 20s percent on average, with standout quarters in 2025Q1–Q2 (~32–34%) and weaker margins in 2024Q3–Q4 (~9–10%). Net cash from operating activities remained positive in all periods, including a peak near $0.96B (2025Q4); investing cash flow was consistently negative, reflecting capital intensity. Financing activity varied, contributing to liquidity in several quarters.

🛡️ Balance Sheet & Liquidity

Total Liabilities run in the mid-to-high $30s billions with equity around $12–14B, implying leverage near 2.5–3x. Long-term Debt remained substantial (roughly $18–20B across periods). Current assets (~~$2.0–$2.7B) vs. current liabilities (~~$3.0–$5.0B) indicate tight near-term liquidity, but the regulated earnings base provides resilience and steady cash generation.

⚠️ Key Drivers & Risks

Drivers: Regulated utility framework and capital investment cycle; stable, commodity-insensitive cash flow.
Risks: High leverage/interest-rate sensitivity; regulatory/regulatory cost pressures and weather-related demand variability.

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"